Liquidia Technologies (NASDAQ:LQDA) is a clinical‐stage biopharmaceutical company focused on the development of precision medicines through its proprietary PRINT® (Particle Replication In Non‐wetting Templates) technology. The company applies its particle-engineering platform to design and manufacture inhaled and injectable formulations, aiming to address diseases with high unmet medical need. Liquidia’s lead programs target pulmonary arterial hypertension (PAH) and other respiratory conditions, leveraging its ability to precisely control particle size, shape and composition for optimal drug delivery.
The company’s most advanced product candidate is Tyvaso® DPI (LIQ861), a dry powder formulation of treprostinil for the treatment of PAH. Developed in collaboration with United Therapeutics Corporation, Tyvaso DPI is designed to offer patients an alternative to nebulized delivery, with the goal of improving convenience and adherence. In addition to PAH, Liquidia’s pipeline includes programs in acute and chronic pain, as well as emerging immunotherapy and vaccine applications that utilize the versatility of its PRINT technology.
Founded on work originating from the University of North Carolina at Chapel Hill, Liquidia Technologies was established to translate academic innovations in nanotechnology into therapeutic solutions. Since its inception, the company has expanded its capabilities in particle engineering, formulation development and clinical manufacturing. The PRINT platform has been applied across small molecules, biologics and combination products, positioning Liquidia as a partner of choice for companies seeking novel drug‐delivery solutions.
Headquartered in Research Triangle Park, North Carolina, Liquidia operates with a global outlook, engaging in strategic partnerships and clinical collaborations worldwide. Under the leadership of President and Chief Executive Officer Douglas Kajdasz and Chief Financial Officer Christine Bovis, the company continues to advance its pipeline through clinical trials and regulatory milestones. With a focus on innovation and patient-centric design, Liquidia aims to bring differentiated therapies to market for complex diseases.
